Mauna Kea Technologies and V7 today announced their partnership to develop a cutting-edge infrastructure for endomicroscopy AI applications with Cellvizio.
Lily Hammond
Partner Marketing Associate at V7
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, and V7, a leading AI and data labeling company, today announced their partnership to develop a cutting-edge infrastructure for AI applications with Cellvizio.
Mauna Kea and V7 will collaborate to establish a strategic data repository of clinically-augmented, curated and annotated Cellvizio images. This foundational data asset will spearhead Mauna Kea’s forthcoming AI-driven innovations:
Future AI-based decision support applications for physicians, in oncology and immunology, benefiting from both in-house and collaborative developments with premier academic and industry partners
Foundational advanced digital biomarker models to expedite drug development, refine disease monitoring and improve the assessment of pathology states in the areas of cancer and food intolerance
Continuous innovation catalyst, based on the actionable in-procedure data generated by Cellvizio, to improve product usability and physician learning experience, or develop proactive maintenance strategies
The entire Mauna Kea Technologies ecosystem, from its partners to its customers, will benefit from this unique combined experience with V7 through the delivery of high-end, future-proof features.
"We are thrilled to join forces with V7 in this pioneering endeavor. This partnership marks a significant milestone in our quest to harness the power of AI for enhancing healthcare outcomes. By integrating V7's advanced AI platform with Mauna Kea's unique in vivo imaging capabilities, we are setting a new standard for precision medicine. This collaboration is a testament to our commitment to innovation and our continuous effort to provide our customers and partners with state-of-the-art, impactful solutions." - Sacha Loiseau, Ph.D. Chairman and CEO of Mauna Kea Technologies
"This partnership with Mauna Kea Technologies represents a significant leap forward in the application of AI within the healthcare sector. By combining our strengths, we are not just advancing the technology itself but also paving the way for a new era of medical diagnostics and treatment - which is why we founded the business back in 2018. Mauna Kea's Cellvizio platform provides an exceptional foundation for AI development, and we are excited to contribute our expertise to create truly transformative healthcare solutions." - Alberto Rizzoli, CEO and Co-Founder of V7
About V7
V7 is a leading training data platform, enabling organizations to seamlessly create, label, query, and manage extensive visual datasets for impactful and trustworthy AI. Trusted by Roche, Miele, Mars Petcare, Sony, Bayer and Merck - V7 has enabled a wide range of pioneering companies to accelerate AI product delivery, standardize AI development and reduce costs in the process - making computer vision a less painful process.
About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit www.maunakeatech.com.
More information on this press release can be found here.
